Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven'sTerms andPolicy

Already have an account? Login here

JIM CRAMER INVESTING PERSONAL FINANCE RETIREMENT TECHNOLOGY MARKETS HOW-TO VIDEO FINANCIAL ADVISOR CENTER

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

MiRagen Enters Into License Agreement With Xencor For Use Of Xtend™ Antibody Technology For Investigational Antibodies To Treat Thyroid Eye Disease

By GlobeNewswire
Dec 17, 2020 7:00 AM EST

MiRagen Therapeutics, Inc. Announces Acquisition Of Viridian Therapeutics, Inc.

By GlobeNewswire
Oct 28, 2020 7:00 AM EDT

MiRagen Announces Internal Review Of Preliminary Topline Data For The Phase 2 SOLAR Clinical Trial Of Cobomarsen In Patients With Cutaneous T-Cell Lymphoma (CTCL)

By GlobeNewswire
Oct 5, 2020 4:05 PM EDT

MiRagen Announces Leadership Transition And Review Of Strategic Alternatives

By GlobeNewswire
Sep 14, 2020 5:00 PM EDT

MiRagen Announces Results Of Meeting With FDA Regarding The Design Of Pivotal Trial For Cobomarsen In ATLL

By GlobeNewswire
Aug 20, 2020 4:05 PM EDT

MiRagen To Present At The 2020 Wedbush PacGrow Healthcare Virtual Conference

By GlobeNewswire
Aug 4, 2020 8:00 AM EDT

MiRagen, Investigators From Goethe University And University Hospital Frankfurt And Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data In Nucleic Acid Therapeutics

By GlobeNewswire
Jul 28, 2020 8:00 AM EDT

Cobomarsen Receives Orphan Drug Designation From The U.S. FDA For The Treatment Of T-cell Lymphoma

By GlobeNewswire
Jul 23, 2020 4:32 PM EDT

MiRagen Regains Compliance With Nasdaq Listing Requirements

By GlobeNewswire
Jul 2, 2020 4:15 PM EDT

MiRagen Announces Encouraging Preclinical Safety And Efficacy Data For Its Next-generation MiR-29 Replacement Product Candidate Intended For The Treatment Of Idiopathic Pulmonary Fibrosis

By GlobeNewswire
Jun 22, 2020 5:08 PM EDT

MiRagen Strengthens Leadership Team With Appointment Of Lee Rauch As Chief Operating Officer

By GlobeNewswire
Jun 18, 2020 4:05 PM EDT

MiRagen To Present At The Jefferies 2020 Virtual Global Healthcare Conference

By GlobeNewswire
May 26, 2020 8:00 AM EDT

MiRagen Therapeutics To Report First Quarter 2020 Financial Results On May 7, 2020

By GlobeNewswire
Apr 23, 2020 8:00 AM EDT

MiRagen Therapeutics To Report Fourth Quarter And Full Year 2019 Financial Results On March 11, 2020

By GlobeNewswire
Feb 20, 2020 8:00 AM EST

MiRagen Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

By GlobeNewswire
Feb 7, 2020 9:00 AM EST

MiRagen Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

By GlobeNewswire
Feb 6, 2020 4:03 PM EST

MiRagen Therapeutics Announces Positive Data For Cobomarsen In Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

By GlobeNewswire
Jan 30, 2020 7:00 AM EST

MiRagen Therapeutics To Present New Cobomarsen Clinical Trial Data For Adult T-Cell Leukemia/Lymphoma At Two Upcoming Conferences

By GlobeNewswire
Jan 23, 2020 8:00 AM EST

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions

© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.